BriaCell Announces Biomarker Findings In Metastatic Breast Cancer Study, Stock Up In Pre-Market

BriaCell Therapeutics presented data at ESMO Congress 2026 showing that changes in PD-L1 expression on circulating CAMLs were linked to survival outcomes in metastatic breast cancer patients treated with immunotherapies, including BriaCell's regimen. The analysis included 111 patients from multiple studies, with significant associations found around three months post-treatment. BriaCell is conducting a Phase 3 study of its Bria-IMT combination regimen, aiming for potential marketing approval.

BriaCell Therapeutics (BCTX) develops targeted immunotherapies for cancer, focusing on 'off-the-shelf' cellular treatments. CEO Dr. Williams discussed their pipeline, including Bria-IMT in a Phase 3 trial for metastatic breast cancer and Bria-PROS+ for prostate cancer, which recently received FDA clearance. The company aims to overcome cost and scaling challenges of traditional therapies.

BriaCell Therapeutics reported positive ASCO 2026 data for Bria-IMT in heavily pretreated metastatic breast cancer. Phase 2 results cited by the company showed 55% survival beyond 1 year and 27% beyond 2 years with the Phase 3-selected regimen; TWiST and quality-of-life analyses from the ongoing Phase 3 Bria-ABC study indicated meaningful benefit with no unexpected safety signals.

BriaCell Therapeutics (Nasdaq: BCTX; TSX: BCT) said its independent Data Safety Monitoring Board reviewed safety data from its pivotal Phase 3 Bria-ABC trial of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer and raised no safety concerns, recommending continuation without modifications. The DSMB issued its sixth consecutive positive recommendation; the study is under FDA Fast Track.

Scotiabank raised its price target for FirstService Corp (FSV) to $175 from $170, citing 2027 growth outlook. The stock trades at $143.97, near InvestingPro’s Fair Value estimate. Q3 results met expectations, with organic growth expected in 2027 but earnings may be limited by higher interest costs. FSV trades at 13x 2027 EV/EBITDA, below its historical average of 18x. The company has raised dividends for 11 consecutive years.

Novartis (NVS) reported that Kisqali, combined with endocrine therapy, reduced the risk of death by 19% in early breast cancer patients over six years, according to the NATALEE trial. The study showed continued improvement in invasive disease-free survival and fewer metastatic recurrences. Novartis plans to present the results at ESMO 2026. NVS stock closed at $156.27, up 1.52%.